Eli Lilly's Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA's Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The expanded label approval is based on P-III KEYNOTE-189 study results assessing Alimta + pembrolizumab + Pt-based CT vs Alimta + Pt-based CT +PBO in 616 patients with mnon-sq NSCLC- regardless of PD-L1 expression
- P-III KEYNOTE-189 results: mPFS (8.8 vs 4.9 mos.); ORR (48% vs 19%); CR (0.5% vs 0.5%); PR (47% vs 18%); mDOR (11.2 vs 7.8 mos.); mOS (NR vs 11.3mos.)
- Alimta is a combination therapy and has received its FDA approval in Jun-2018 for 1L mnon-sq NSCLC in combination with pembrolizumab and carboplatin
Ref: Eli Lilly | Image: Eli Lilly
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com